JP7784103B2 - Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング - Google Patents

Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング

Info

Publication number
JP7784103B2
JP7784103B2 JP2019534737A JP2019534737A JP7784103B2 JP 7784103 B2 JP7784103 B2 JP 7784103B2 JP 2019534737 A JP2019534737 A JP 2019534737A JP 2019534737 A JP2019534737 A JP 2019534737A JP 7784103 B2 JP7784103 B2 JP 7784103B2
Authority
JP
Japan
Prior art keywords
compound
cancer
acid
group
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019534737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514278A (ja
JP2020514278A5 (https=
Inventor
ニマガダ シュリダール
ジー ポンパー マーティン
チャタージー サミット
ジー レスニアク ウォイチェフ
クマール ディラージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2020514278A publication Critical patent/JP2020514278A/ja
Publication of JP2020514278A5 publication Critical patent/JP2020514278A5/ja
Priority to JP2022207606A priority Critical patent/JP7680759B2/ja
Priority to JP2025075768A priority patent/JP2025118743A/ja
Application granted granted Critical
Publication of JP7784103B2 publication Critical patent/JP7784103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/225—Microparticles, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acoustics & Sound (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019534737A 2016-12-23 2017-12-21 Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング Active JP7784103B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022207606A JP7680759B2 (ja) 2016-12-23 2022-12-23 Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング
JP2025075768A JP2025118743A (ja) 2016-12-23 2025-04-30 Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438575P 2016-12-23 2016-12-23
US62/438,575 2016-12-23
US201762519534P 2017-06-14 2017-06-14
US62/519,534 2017-06-14
PCT/US2017/068025 WO2018119313A1 (en) 2016-12-23 2017-12-21 Tumor and immune cell imaging based on pd-l1 expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022207606A Division JP7680759B2 (ja) 2016-12-23 2022-12-23 Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング

Publications (3)

Publication Number Publication Date
JP2020514278A JP2020514278A (ja) 2020-05-21
JP2020514278A5 JP2020514278A5 (https=) 2021-01-14
JP7784103B2 true JP7784103B2 (ja) 2025-12-11

Family

ID=62627749

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019534737A Active JP7784103B2 (ja) 2016-12-23 2017-12-21 Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング
JP2022207606A Active JP7680759B2 (ja) 2016-12-23 2022-12-23 Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング
JP2025075768A Pending JP2025118743A (ja) 2016-12-23 2025-04-30 Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022207606A Active JP7680759B2 (ja) 2016-12-23 2022-12-23 Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング
JP2025075768A Pending JP2025118743A (ja) 2016-12-23 2025-04-30 Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング

Country Status (11)

Country Link
US (1) US11607466B2 (https=)
EP (1) EP3558395A4 (https=)
JP (3) JP7784103B2 (https=)
KR (2) KR102662725B1 (https=)
CN (1) CN110366432A (https=)
AU (1) AU2017382282B9 (https=)
BR (1) BR112019012986A2 (https=)
CA (1) CA3048229A1 (https=)
IL (1) IL267572B2 (https=)
MX (1) MX2019007615A (https=)
WO (1) WO2018119313A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN109512798B (zh) * 2019-01-15 2022-05-13 南京从一医药科技有限公司 一种用于抗肿瘤免疫治疗的药物组合物纳米体系
CN111662270A (zh) * 2019-03-05 2020-09-15 中国医学科学院药物研究所 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途
CN110898234B (zh) * 2019-12-25 2020-12-22 河南大学 一种二维铋纳米复合材料及其制备方法和应用
TWI833056B (zh) 2019-12-31 2024-02-21 財團法人工業技術研究院 核酸藥物複合體以及其用途
CN112067586B (zh) * 2020-06-24 2021-08-03 江南大学 一种基于荧光淬灭拉曼增强的前列腺特异性抗原双信号光谱分析方法
CA3188677A1 (en) * 2020-08-07 2022-02-10 Sridhar Nimmagadda Imaging and targeting programmed death ligand-1 (pd-li) expression
DE102020130954A1 (de) 2020-11-23 2022-05-25 Universität Duisburg-Essen Markierungspartikel für Raman-Streuung und/oder Fluoreszenz-Strahlung
CN114853851B (zh) * 2021-02-04 2023-08-15 南方医科大学南方医院 靶向pd-l1多肽探针及其在制备pet显像剂中的应用
CN113341023B (zh) * 2021-06-30 2022-12-23 大连医科大学附属第一医院 一种基于液质联用的血清二氨基庚二酸的检测试剂盒及检测方法与应用
WO2023014999A1 (en) * 2021-08-06 2023-02-09 The Johns Hopkins University Aluminum fluoride radiosynthesis of [18f]dk222
CN115364247A (zh) * 2021-09-15 2022-11-22 中国人民解放军海军军医大学第一附属医院 一种靶向显影剂、制备方法及其应用
CN114010655B (zh) * 2021-11-02 2023-02-03 安徽医科大学第一附属医院 一种识别和降解前列腺癌细胞表面的pd-l1的金纳米星及其制备方法和应用
CN114569745A (zh) * 2022-03-18 2022-06-03 哈尔滨医科大学 一种靶向pd-l1的多肽pet分子成像探针及其制备方法与应用
AU2024344671A1 (en) * 2023-09-20 2026-03-26 Trimt Gmbh Functionalized peptides for in-vivo addressing of pd-l1 expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
WO2016086021A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542371A (en) * 2003-03-19 2008-10-31 Universitatsspital Basel Radiolabeled conjugates based on substance P and the uses thereof
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
US20140316255A1 (en) * 2011-09-02 2014-10-23 Ellis Garai Raman Imaging Devices and Methods of Molecular Imaging
US11268958B2 (en) * 2012-09-14 2022-03-08 The Johns Hopkins University Bacteria-specific labeled substrtates as imaging biomarkers to diagnose, locate, and monitor infections
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
HUE054306T2 (hu) * 2016-05-19 2021-08-30 Bristol Myers Squibb Co Immunmodulátorok PET-képalkotás számára
CN107869033B (zh) * 2016-09-26 2020-10-02 青岛胶南海尔洗衣机有限公司 一种干衣机用正反转风扇及干衣机

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
WO2016086021A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Angew Chem Int Ed., 2015, vol. 54, no. 40, p. 11760-11764, DOI: 10.1002/anie.201506225

Also Published As

Publication number Publication date
EP3558395A4 (en) 2020-08-12
KR20240023665A (ko) 2024-02-22
IL267572A (en) 2019-08-29
US11607466B2 (en) 2023-03-21
EP3558395A1 (en) 2019-10-30
AU2017382282B9 (en) 2025-02-13
JP2020514278A (ja) 2020-05-21
KR102662725B1 (ko) 2024-04-30
JP2025118743A (ja) 2025-08-13
BR112019012986A2 (pt) 2019-12-03
IL267572B1 (en) 2024-10-01
WO2018119313A1 (en) 2018-06-28
CN110366432A (zh) 2019-10-22
JP7680759B2 (ja) 2025-05-21
US20190314531A1 (en) 2019-10-17
CA3048229A1 (en) 2018-06-28
JP2023052071A (ja) 2023-04-11
IL267572B2 (en) 2025-02-01
AU2017382282A1 (en) 2019-07-11
AU2017382282B2 (en) 2025-01-30
MX2019007615A (es) 2019-11-05
KR20190102018A (ko) 2019-09-02

Similar Documents

Publication Publication Date Title
JP7680759B2 (ja) Ｐｄ－ｌ１発現に基づく腫瘍および免疫細胞イメージング
Parry et al. In vitro and in vivo evaluation of 64Cu-labeled DOTA− linker− bombesin (7− 14) analogues containing different amino acid linker moieties
Miao et al. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein
Shokeen et al. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET)
Da Pieve et al. Efficient [18F] AlF radiolabeling of ZHER3: 8698 affibody molecule for imaging of HER3 positive tumors
Hofström et al. HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [99mTc (CO) 3]+-labeled affibody molecules
Edwards et al. Agonist− Antagonist Dilemma in Molecular Imaging: Evaluation of a Monomolecular Multimodal Imaging Agent for the Somatostatin Receptor
Moreau et al. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes
Ghosh et al. Multimodal chelation platform for near-infrared fluorescence/nuclear imaging
Garrison et al. Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN (7− 14) NH2 structural paradigm in a prostate cancer model
Färber et al. Therapeutic radiopharmaceuticals targeting integrin αvβ6
Ikotun et al. The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86
Kuil et al. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression
Sharma et al. CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET
Kanellopoulos et al. Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology
US20230271923A1 (en) Imaging and targeting programmed death ligand-1 (pd-li) expression
Zou et al. Radiopharmaceuticals targeting gastrin-releasing peptide receptor for diagnosis and therapy of prostate cancer
Huang et al. Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer
Kim et al. Iodine 125‐labeled mesenchymal–epithelial transition factor binding peptide‐click‐cRGDyk heterodimer for glioma imaging
EA052886B1 (ru) Визуализация опухолевых и иммунных клеток на основе экспрессии pd-l1
Dilworth et al. The radiopharmaceutical chemistry of Gallium (III) and Indium (III) for SPECT imaging
Schreck et al. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me
Huynh The Evaluation of Radiometal Labeled Biomolecules for Imaging and Therapeutic Applications
Lin Molecular Imaging of αvβ6–Positive Tumors and Pancreatic β-Cell Mass by Radiolabeled Peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221223

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230112

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230117

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230303

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251121

R150 Certificate of patent or registration of utility model

Ref document number: 7784103

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150